# Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

> **NCT02097303** · PHASE2 · COMPLETED · sponsor: **Carolina Research Professionals, LLC** · enrollment: 36 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone

## Key facts

- **NCT ID:** NCT02097303
- **Lead sponsor:** Carolina Research Professionals, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097303, "Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02097303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*